J A Glaspy

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint The potential for anemia treatment to improve survival in cancer patients
    John A Glaspy
    Department of Medicine, UCLA School of Medicine, Los Angeles, California, USA
    Oncology (Williston Park) 16:35-40. 2002
  2. ncbi request reprint Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma
    Lynn K Gordon
    Department of Ophthalmology, and the Jules Stein Eye Institute, and the UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 100 Stein Plaza, Los Angeles, CA 90095 7000, USA
    Control Clin Trials 25:400-7. 2004
  3. ncbi request reprint Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa
    John Glaspy
    UCLA, School of Medicine, 100 UCLA Medical Plaza, Suite 550, Los Angeles, CA 90095 6956, USA
    Eur J Cancer 41:1140-9. 2005
  4. ncbi request reprint Cancer patient survival and erythropoietin
    John A Glaspy
    Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, CA 90095 6956, USA
    J Natl Compr Canc Netw 3:796-804. 2005
  5. ncbi request reprint Erythropoiesis-stimulating agents in oncology
    John A Glaspy
    Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, California 90095 6956, USA
    J Natl Compr Canc Netw 6:565-75. 2008
  6. pmc Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
    Antoni Ribas
    Division of Hematology Oncology, 11 934 Factor Building, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, CA 90095 1782, USA
    J Transl Med 10:236. 2012
  7. ncbi request reprint Update on safety of ESAs in cancer-induced anemia
    John Glaspy
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 6956, USA
    J Natl Compr Canc Netw 10:659-66. 2012
  8. pmc Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
    Franziska Niehr
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles UCLA, USA
    J Transl Med 9:76. 2011
  9. pmc Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma
    Antoni Ribas
    University of California Los Angeles UCLA, CA, USA
    J Transl Med 8:89. 2010
  10. pmc Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
    Begona Comin-Anduix
    Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, CA, USA
    J Transl Med 6:22. 2008

Detail Information

Publications63

  1. ncbi request reprint The potential for anemia treatment to improve survival in cancer patients
    John A Glaspy
    Department of Medicine, UCLA School of Medicine, Los Angeles, California, USA
    Oncology (Williston Park) 16:35-40. 2002
    ..This article reviews the data available regarding the impact of anemia on the survival of cancer patients...
  2. ncbi request reprint Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma
    Lynn K Gordon
    Department of Ophthalmology, and the Jules Stein Eye Institute, and the UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 100 Stein Plaza, Los Angeles, CA 90095 7000, USA
    Control Clin Trials 25:400-7. 2004
    ..To report the protocol for surveillance of the eye and vision in a clinical trial of MART1-transduced dendritic cells for metastatic melanoma...
  3. ncbi request reprint Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa
    John Glaspy
    UCLA, School of Medicine, 100 UCLA Medical Plaza, Suite 550, Los Angeles, CA 90095 6956, USA
    Eur J Cancer 41:1140-9. 2005
    ....
  4. ncbi request reprint Cancer patient survival and erythropoietin
    John A Glaspy
    Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, CA 90095 6956, USA
    J Natl Compr Canc Netw 3:796-804. 2005
    ..For the present, it is prudent to withhold ESP therapy unless hemoglobin concentrations fall below 12 g/dL and to titrate treatment to maintain a target of 12 g/dL, with adjustments in therapy to insure that levels do not exceed 13 g/dL...
  5. ncbi request reprint Erythropoiesis-stimulating agents in oncology
    John A Glaspy
    Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, California 90095 6956, USA
    J Natl Compr Canc Netw 6:565-75. 2008
    ..This article reviews relevant preclinical and clinical available data to help improve understanding and guide decision making...
  6. pmc Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
    Antoni Ribas
    Division of Hematology Oncology, 11 934 Factor Building, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, CA 90095 1782, USA
    J Transl Med 10:236. 2012
    ..The similarly fully human anti-CTLA4 antibody tremelimumab had been developed in the clinic at a fixed rate infusion, resulting in very prolonged infusion times. A new formulation of tremelimumab allowed testing a shorter infusion time...
  7. ncbi request reprint Update on safety of ESAs in cancer-induced anemia
    John Glaspy
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 6956, USA
    J Natl Compr Canc Netw 10:659-66. 2012
    ..Until additional safety data are forthcoming, ESAs should be used only to treat chemotherapy-induced anemia, with the goal of preventing transfusions. Patients and physicians should be aware of the safety data for these products...
  8. pmc Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
    Franziska Niehr
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles UCLA, USA
    J Transl Med 9:76. 2011
    ..A molecular linkage between the MAPK and the LKB1-AMPK energy sensor pathways suggests that combined MAPK oncogene inhibition and metabolic modulation of AMPK would be more effective than either manipulation alone in melanoma cell lines...
  9. pmc Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma
    Antoni Ribas
    University of California Los Angeles UCLA, CA, USA
    J Transl Med 8:89. 2010
    ....
  10. pmc Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
    Begona Comin-Anduix
    Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, CA, USA
    J Transl Med 6:22. 2008
    ..CTLA4-blocking antibodies induce tumor regression in a subset of patients with melanoma. Analysis of immune parameters in peripheral blood may help define how responses are mediated...
  11. pmc Use of complementary/alternative therapies by women with advanced-stage breast cancer
    Joannie Shen
    Laboratory of Clinical Sciences, National Institute of Alcoholism and Alcohol Abuse, National Institutes of Health, Bethesda, MD, USA
    BMC Complement Altern Med 2:8. 2002
    ....
  12. ncbi request reprint Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia
    John Glaspy
    Clinical Research Unit, UCLA School of Medicine, Los Angeles, California 90095 7077, USA
    Oncology (Williston Park) 20:29-32. 2006
    ..Synchronous administration of darbepoetin alfa with chemotherapy is a convenient option for patients with chemotherapy-induced anemia, with clinical trials showing it to be an effective treatment strategy...
  13. ncbi request reprint Hematopoietic management in oncology practice. Part 2. Erythropoietic factors
    John A Glaspy
    Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, California, USA
    Oncology (Williston Park) 17:1724-30; discussion 1731-2, 1735, 1739. 2003
    ..Thrombopoietic factors and progenitor cell-mobilizing factors are also briefly addressed...
  14. ncbi request reprint A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease
    John A Glaspy
    Division of Hematology Oncology, Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095 6956, USA
    Cancer 97:1312-20. 2003
    ..Darbepoetin alpha, a new erythropoietic agent, has longer serum residence time, allowing it to be administered less frequently...
  15. doi request reprint Erythropoietin in cancer patients
    John A Glaspy
    Division of Hematology Oncology, Department of Medicine, School of Medicine, University of California, Los Angeles, California 90095, USA
    Annu Rev Med 60:181-92. 2009
    ..Although the preponderance of the data suggests that ESAs do not alter survival when used to treat chemotherapy-induced anemia, large well-controlled trials addressing this issue are needed...
  16. ncbi request reprint Can erythropoietin therapy improve survival?
    John Glaspy
    University of California, Los Angeles School of Medicine, 90095, USA
    Oncology 67:5-11. 2004
    ..These results suggest that treatment of anaemic patients with cancer with epoetin beta is effective and safe...
  17. ncbi request reprint Hematopoietic management in oncology practice. Part 1. Myeloid growth factors
    John A Glaspy
    Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, California, USA
    Oncology (Williston Park) 17:1593-603. 2003
    ..In randomized trials, rhG-CSF has consistently decreased the duration of neutropenia during all cycles of chemotherapy and reduced the risk of infection by 50% or more. Trials of rhGM-CSF have not reported consistent results...
  18. ncbi request reprint Entering a new era in the management of tumor-associated involution
    John A Glaspy
    Division of Hematology Oncology, Jonsson Comprehensive Cancer Center, UCLA School of Medicine, Los Angeles, California 90095, USA
    J Support Oncol 3:51-2. 2005
  19. ncbi request reprint The development of erythropoietic agents in oncology
    John A Glaspy
    Division of Hematology Oncology, Department of Medicine, UCLA School of Medicine, Los Angeles, CA 90095 6956, USA
    Expert Opin Emerg Drugs 10:553-67. 2005
    ..A large body of data suggests that these agents are safe when used in accordance with the package inserts. The data bearing upon these issues will be reviewed and three new agents entering clinical development will be described...
  20. ncbi request reprint Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon)
    John Glaspy
    University of California, Los Angeles School of Medicine, Los Angeles, CA 90095, USA
    Oncology 69:8-16. 2005
    ..Ongoing studies are expected to lead to a greater understanding of the optimal use of epoetins in cancer-related anaemia...
  21. ncbi request reprint Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial
    John Glaspy
    University of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA
    J Clin Oncol 24:2290-7. 2006
    ..This noninferiority study systematically compares efficacy and safety of DA and EA using common doses and schedules used in clinical practice...
  22. ncbi request reprint Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy
    John A Glaspy
    UCLA School of Medicine, UCLA Oncology Center, Los Angeles, California, USA
    Oncology (Williston Park) 16:23-9. 2002
    ..A dose increase to 5.0 microg/kg of darbepoetin alfa administered every 2 weeks may be appropriate in patients with an inadequate initial response...
  23. doi request reprint Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms
    John A Glaspy
    Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, California 90095 6956, USA
    Cancer 115:1121-31. 2009
    ..This study evaluated a starting dose of epoetin-alpha 120,000 U once every 3 weeks for chemotherapy-induced anemia using early and late initiation regimens...
  24. doi request reprint Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma
    John Glaspy
    Department of Medicine, UCLA Medical Center, Los Angeles, CA 90095, USA
    Cancer 115:5228-36. 2009
    ....
  25. pmc Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes
    J Glaspy
    Department of Medicine Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, 100 UCLA Medical Plaza, Suite 550, Los Angeles, CA 90095 6996 USA
    Br J Cancer 102:301-15. 2010
    ..To evaluate recent safety concerns regarding ESAs, we carried out a meta-analysis of controlled ESA oncology trials to examine whether ESA use affects survival, disease progression and risk of venous-thromboembolic events...
  26. ncbi request reprint Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency
    John A Glaspy
    Department of Medicine, UCLA School of Medicine, Los Angeles, California, USA
    Oncology (Williston Park) 16:71-7. 2002
    ..The characteristics of darbepoetin alfa suggest the ability to improve overall quality of erythropoietic therapy, which may increase its utilization in patients who would benefit from such treatment...
  27. pmc Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
    J A Glaspy
    Br J Cancer 87:268-76. 2002
    ..Therapy with darbepoetin alfa is safe and effective in producing a dose-related increase in haemoglobin levels in patients with cancer receiving chemotherapy...
  28. ncbi request reprint T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein
    L H Butterfield
    Division of Surgical Oncology, Department of Chemistry and Biochemistry, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA
    J Immunol 166:5300-8. 2001
    ....
  29. ncbi request reprint CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells
    A Ribas
    Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, California 90095, USA
    Cancer Res 61:8787-93. 2001
    ..In conclusion, maturation of AdVMART1-transduced DCs through the CD40 ligation pathway can promote a protective CD8 T-cell-mediated immunity that is independent of CD4 T-cell help...
  30. ncbi request reprint Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells
    R L Paquette
    Department of Medicine, The University of California at Los Angeles, 90095 1678, USA
    J Leukoc Biol 64:358-67. 1998
    ..These results demonstrate an important role for IFN-alpha in the generation of DCs with potent antigen-presenting capabilities from peripheral blood monocytes...
  31. pmc Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma
    Lisa H Butterfield
    Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Immunother 31:294-309. 2008
    ..Responses in CD8+ and CD4+ T cells to additional antigens were noted in 2 patients. The AdVMART1-transduced DC vaccine was safe and immunogenic in patients with metastatic melanoma...
  32. ncbi request reprint Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy
    Antoni Ribas
    Department of Surgery, Division of Surgical Oncology, UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, California, USA
    J Immunother 27:354-67. 2004
    ..Sequential CTLA4 blockade may enhance the immune activity of DC-based immunotherapy...
  33. ncbi request reprint Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade)
    Lana Y Schumacher
    Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles 90095, USA
    J Immunol 176:4757-65. 2006
    ..In conclusion, the proteasome inhibitor bortezomib can pharmacologically sensitize tumor cells to the lytic effects of DC-activated immune effector cells...
  34. ncbi request reprint Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology Surgery, University of California at Los Angeles, CA, USA
    J Clin Oncol 23:8968-77. 2005
    ..A phase I trial was conducted to test the safety of CP-675,206...
  35. ncbi request reprint Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma
    Lisa H Butterfield
    Department of Surgery, Division of Surgical Oncology, UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
    Clin Cancer Res 9:998-1008. 2003
    ..The purpose of this study was to determine the toxicity and immunological effects of three different doses and two routes of administration of autologous dendritic cells (DCs) pulsed with the MART-1(27-35) immunodominant epitope...
  36. ncbi request reprint Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer
    R L Paquette
    Departments of Medicine and Biostatistics, University of California at Los Angeles, Los Angeles, CA, USA
    Blood 96:2385-90. 2000
    ..Therefore, ex vivo expanded PBPC are capable of ameliorating posttransplantation neutropenia, thrombocytopenia, and anemia in patients receiving high-dose chemotherapy...
  37. ncbi request reprint Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells
    Jennifer A Wargo
    Department of Surgery, Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Cancer Gene Ther 12:516-27. 2005
    ..In conclusion, protective immunity after tumor antigen gene-modified DC immunization requires collaboration between CD4+ and CD8+ T cells and NK cells...
  38. ncbi request reprint T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer
    Lisa H Butterfield
    Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, California, USA
    Clin Cancer Res 9:5902-8. 2003
    ..We wished to test the hypothesis that AFP peptide-reactive T cells could be expanded in vivo in HCC patients immunized with these four AFP peptides...
  39. ncbi request reprint Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
    M D Pegram
    Department of Medical Oncology, The University of California at Los Angeles, USA
    J Clin Oncol 16:2659-71. 1998
    ..v.) administration of recombinant, humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) plus cisplatin (CDDP) in a phase II, open-label, multicenter clinical trial for patients with HER2/neu-overexpressing metastatic breast cancer...
  40. doi request reprint Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade
    Antoni Ribas
    Division of Hematology Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California 90095 1782, USA
    Clin Cancer Res 15:390-9. 2009
    ..In this study, biopsies of selected accessible tumor lesions from patients treated with tremelimumab were examined to further elucidate the mechanism of its antitumor activity...
  41. doi request reprint Do we need a different set of response assessment criteria for tumor immunotherapy?
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, Los Angeles, California 90095 1782, USA
    Clin Cancer Res 15:7116-8. 2009
    ..In this issue of Clinical Cancer Research, Wolchok et al. attempt to address this peculiarity by proposing a new set of criteria termed immune-related response criteria...
  42. pmc Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology, University of California at Los Angeles, Los Angeles, California 90095 1782, USA
    Clin Cancer Res 15:6267-76. 2009
    ..The combination was tested in a phase I clinical trial in patients with advanced melanoma...
  43. ncbi request reprint Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma
    Bradley R Straatsma
    Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, California 90095, USA
    Am J Ophthalmol 143:958-969. 2007
    ..To determine the ocular safety of CP-675,206 (Pfizer, New York, New York, USA), a fully human anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody in clinical trials of immunotherapy of metastatic melanoma...
  44. pmc Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma
    William D Tap
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
    Neoplasia 12:637-49. 2010
    ..We sought to investigate the efficacy of PLX4032 (BRAF inhibitor) to identify patterns/predictors of response/resistance and to study the effects of BRAF in melanoma...
  45. ncbi request reprint Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery
    Ronald L Paquette
    Department of Medicine, Division of Hematology Oncology, 42 121 UCLA Center for the Health Sciences, 10833 Le Conte Avenue, Los Angeles, CA 90095 1678, USA
    Exp Hematol 30:374-80. 2002
    ..The aim of this study was to evaluate the effect of various ex vivo expansion conditions on the cell products and their ability to accelerate hematopoietic recovery in patients undergoing stem cell transplantation...
  46. ncbi request reprint Cancer immunotherapy using gene-modified dendritic cells
    Antoni Ribas
    Departments of Surgery, Medicine, Division of Hematology Oncology, 11 934 Factor Bldg UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
    Curr Gene Ther 2:57-78. 2002
    ..These data may help in the translation of this promising approach to the clinic...
  47. ncbi request reprint Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays
    Begona Comin-Anduix
    Department of Surgery, Division of Surgical, University of California at Los Angeles, Los Angeles, California, USA
    Clin Cancer Res 12:107-16. 2006
    ..Define an immunologic response using the tetramer and enzyme-linked immunospot (ELISPOT) assays...
  48. ncbi request reprint Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice
    Antoni Ribas
    Division of Hematology Oncology, Department of Medicine, University of California, Los Angeles, 90095, USA
    Cancer Immunol Immunother 55:663-71. 2006
    ..3) In sensitive targets a putative activating NK ligand in DC-stimulated NK cells from CD8alphaKO mice signals directly to PI3-K, but is distinct from NKG2D...
  49. ncbi request reprint Current developments in cancer vaccines and cellular immunotherapy
    Antoni Ribas
    Division of Hematology Oncology, Department of Medicine, University of California Los Angeles, 90095 1782, USA
    J Clin Oncol 21:2415-32. 2003
    ....
  50. ncbi request reprint Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, CA 90095, USA
    J Immunol 172:4762-9. 2004
    ..Elucidation of the signaling events that activate these effective cytotoxic cells and the putative suppressive mechanisms in a wild-type environment may provide means to enhance the clinical activity of DC-based approaches...
  51. ncbi request reprint A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides
    Lisa H Butterfield
    Department of Medicine, Surgery and Immunology, Hillman Cancer Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 12:2817-25. 2006
    ..We conclude that the human T cell repertoire is capable of responding to the AFP self antigen after the administration of AFP peptide-pulsed DC even in an environment of high circulating levels of this oncofetal antigen...
  52. ncbi request reprint Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo
    R L Paquette
    UCLA Department of Medicine, Division of Hematology Oncology, Los Angeles, CA 90095 1678, USA
    Leukemia 16:1484-9. 2002
    ..The therapeutic activity of IFN-alpha in CML may be due to its ability to stimulate the generation of DCs that can present CML-specific antigens. Resistance to IFN-alpha may result when DC differentiation becomes impaired...
  53. ncbi request reprint alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination
    W S Meng
    Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, California 90095, USA
    Cancer Res 61:8782-6. 2001
    ..This cell-free mode of immunization is better suited for large-scale vaccine efforts for patients with hepatocellular carcinoma...
  54. ncbi request reprint Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer
    W J Aronson
    Department of Urology, University of California, Los Angeles, School of Medicine, Los Angeles, California 90095-1738, USA
    Urology 58:283-8. 2001
    ..The potential for this diet to prevent the development and progression of prostate cancer by way of altered COX-2 expression and prostaglandin production in prostatic tissue requires further study...
  55. ncbi request reprint Therapeutic options in the management of renal cell carcinoma
    John A Glaspy
    Bowyer Oncology Center, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    Semin Oncol 29:41-6. 2002
    ..Expansion of activated T cells in blood during treatment with these two cytokines seems to relate to clinical efficacy in patients with RCC...
  56. pmc Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2
    Naoko Kobayashi
    Department of Urology, Division of Clinical Nutrition and Hematology Oncology, University of California, Los Angeles School of Medicine, 90095 1738, USA
    Clin Cancer Res 12:4662-70. 2006
    ....
  57. ncbi request reprint Long-chain n-3-to-n-6 polyunsaturated fatty acid ratios in breast adipose tissue from women with and without breast cancer
    Dilprit Bagga
    Division of Hematology Oncology, Department of Medicine, University of California, Los Angeles School of Medicine, Los Angeles, CA 90095, USA
    Nutr Cancer 42:180-5. 2002
    ..09). We conclude that total n-6 PUFAs may be contributing to the high risk of breast cancer in the United States and that LC n-3 PUFAs, derived from fish oils, may have a protective effect...
  58. ncbi request reprint Novel interactions of vitamin E and estrogen in breast cancer
    Hilda Chamras
    Division of Hematology Oncology, Department of Medicine, University of California at Los Angeles, School of Medicine 90095 1678, USA
    Nutr Cancer 52:43-8. 2005
    ..This provides evidence that vitamin E may inhibit ER-positive cell growth by altering the cellular response to estrogen...
  59. ncbi request reprint Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
    Jeffrey Crawford
    Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 95:888-95. 2002
    ..Relationships among hemoglobin, functional status, and patient reported QOL have not been well characterized...
  60. ncbi request reprint Standards of care for anemia management in oncology: focus on lung carcinoma
    Corey J Langer
    Department of Thoracic Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Cancer 95:613-23. 2002
    ..Evidence is growing that anemia can have a profound impact on the patient's quality of life, often manifested as the patient's inability to function normally...
  61. ncbi request reprint Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines
    Antoni Ribas
    Department of Surgery, University of California at Los Angeles, 90095 1782, USA
    Cancer Gene Ther 9:875-83. 2002
    ..In conclusion, in this animal model, IL-12 production by gene-modified DC leads to a cytokine-induced dose-dependent inhibition of antigen-specific antitumor protection...
  62. doi request reprint Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study
    Robert E Smith
    South Carolina Oncology Associates, Columbia, SC, USA
    J Clin Oncol 26:1040-50. 2008
    ..The efficacy and safety of darbepoetin alpha (DA) for treating patients with active cancer and anemia not receiving or planning to receive cytotoxic chemotherapy or myelosuppressive radiotherapy was evaluated...
  63. ncbi request reprint High-molecular weight iron dextran: a wolf in sheep's clothing?
    George M Rodgers
    J Am Soc Nephrol 19:833-4. 2008